Incidence of Secondary Neoplasia in Patients with Neuroendocrine Tumor: An Analysis of the SwissNET Database Abstract #821

Introduction: NET are believed to be associated with an increased risk for secondary neoplasia. Previous studies suggest incidence rates between 7% and 46%.
Aim(s): To determine the incidence rate and related mortality based on the Swiss NeuroEndocrine Tumour registry (SwissNET).
Materials and methods: Two-hundred and eighty-five men (55%) and 237 women (45%) with sporadic NET were included. Four-hundred and fifteen NET were localized in the GI-tract (79.5%), 55 in the lung (10.5%). In 40 cases (8%) primary site was unknown or at other sites (12 patients, 2%). Median age at diagnosis was 59 years, median follow up 318 days.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: nnika Blank

To read results and conclusion, please login ...

Further abstracts you may be interested in

#407 Co-existing Type-1 Gastric Neuroendocrine Tumors (NETs) and Adenocarcinoma in Autoimmune Associated Atrophic Gastritis
Introduction: Autoimmune gastritis (AIG) causes oxyntic gland atrophy. This condition is often associated with Type-1 gastric NET secondary to achlorhydria and hypergastrinemia. Similar to atrophic gastritis in non-autoimmune conditions, AIG is associated with intestinal metaplasia that could progress to glandular dysplasia.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Laura Tang
Authors: Tang L
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET
#1797 An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: James C Yao
Authors: Yao J C, Fazio N, Pavel M, Strosberg J, ...
Keywords: PDR001, immunotherapy, NET
#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.
Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Rodney Pommier
#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni